Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 13/20 | 0.58 |
| ▸ | ADRA2B | P18089 | 13/20 | 0.58 |
| ▸ | ADRA2C | P18825 | 13/20 | 0.58 |
| ▸ | MAOA | P21397 | 10/20 | 0.58 |
| ▸ | MAOB | P27338 | 10/20 | 0.58 |
| ▸ | NISCH | Q9Y2I1 | 8/20 | 0.58 |
| ▸ | HTR1A | P08908 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17887784 | 0.86 | MAOA (0.45) | ADRA2AADRA2BADRA2CMAOAMAOB | |
| SCHEMBL17887782 | 0.77 | ADRA2A (0.49) | ADRA2AADRA2BADRA2CMAOAMAOB | |
| SCHEMBL3717495 | 0.76 | ADRA2B (0.57) | ADRA2AADRA2BADRA2CMAOAMAOB | |
| SCHEMBL17887596 | 0.75 | MAOA (0.59) | ADRA2AADRA2BADRA2CMAOAMAOB | |
| SCHEMBL17887853 | 0.74 | ADRA2A (1.00) | ADRA2AADRA2BADRA2CMAOAMAOB | |
| SCHEMBL2778291 | 0.71 | ADRA2A (0.67) | ADRA2AADRA2BADRA2CMAOAMAOB | |
| SCHEMBL17887786 | 0.69 | ADRA2A (0.65) | ADRA2AADRA2BADRA2CMAOAMAOB | |
| SCHEMBL11246125 | 0.68 | ADRA2B (0.61) | ADRA2AADRA2BADRA2CMAOAMAOB | |
| SCHEMBL545847 | 0.65 | NISCH (0.50) | ADRA2AADRA2BADRA2CMAOAMAOB | |
| SCHEMBL9199669 | 0.65 | ADRA2B (0.64) | ADRA2AADRA2BADRA2CMAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2016105448-A1 | IMIDAZOLINE RECEPTOR TYPE 1 LIGANDS FOR USE AS THERAPEUTICS | RIDEOUT DARRYL (US) | 2016-06-30 | — | — | WO | disclosed |